靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2016-07-06 |
靶点- |
|
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multimodality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury
This is the proof of concept study with multi-modality approach (using intra-thecal bioactive peptides, stem cells, laser and transcranial IV laser and Median Nerve stimulation as adjuvants) in cases of brain death due to traumatic brain injury having diffuse axonal injury to document possibility of reversal of brain death (BD).
100 项与 Revita Life Sciences 相关的临床结果
0 项与 Revita Life Sciences 相关的专利(医药)
100 项与 Revita Life Sciences 相关的药物交易
100 项与 Revita Life Sciences 相关的转化医学